NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Rodgers M, Epstein D, Bojke L, et al. Etanercept, Infliximab and Adalimumab for the Treatment of Psoriatic Arthritis: A Systematic Review and Economic Evaluation. Southampton (UK): NIHR Journals Library; 2011 Feb. (Health Technology Assessment, No. 15.10.)

Cover of Etanercept, Infliximab and Adalimumab for the Treatment of Psoriatic Arthritis: A Systematic Review and Economic Evaluation

Etanercept, Infliximab and Adalimumab for the Treatment of Psoriatic Arthritis: A Systematic Review and Economic Evaluation.

Show details

Appendix 1Literature search strategies

Full details of all databases searched and search strategies are provided below. Numbers in brackets reflect the number of hits retrieved.

The search strategy was designed for searching MEDLINE through the OvidSP interface and was adapted as appropriate for all other databases searched, taking into account differences in indexing terms and search syntax for each database.

Clinical effectiveness: search for RCTS

MEDLINE: OvidSP

The MEDLINE search covered the date range 1950 to week 5 May 2009 for adalimumab and 1 April 2004 to week 5 May 2009, using the search field ‘ed: Entry Date’, for etanercept and infliximab. The search was carried out on 9 June 2009 and identified 399 records.

The strategy uses the Cochrane Highly Sensitive Search Strategy for identifying randomised trials in MEDLINE, sensitivity-maximising version (lines 1–11).202

  1. randomized controlled trial.pt. (272,711)
  2. controlled clinical trial.pt. (79,394)
  3. randomized.ab. (182,345)
  4. placebo.ab. (112,659)
  5. drug therapy.fs. (1,317,603)
  6. randomly.ab. (132,262)
  7. trial.ab. (189,408)
  8. groups.ab. (909,284)
  9. or/1-8 (2,406,033)
  10. (animals not (humans and animals)).sh. (3,290,537)
  11. 9 not 10 (2,040,011)
  12. Arthritis, Psoriatic/ (2223)
  13. (psoria$adj2 (arthrit$or arthropath$)).ti,ab. (3596)
  14. 12 or 13 (4138)
  15. (etanercept or enbrel).ti,ab,rn. (2085)
  16. (infliximab or remicade).ti,ab,rn. (4715)
  17. 15 or 16 (5890)
  18. 11 and 14 and 17 (450)
  19. (200404$or 200405$or 200406$or 200407$or 200408$or 200409$ or 200410$or 200411$or 200412$or 2005$or 2006$or 2007$or 2008$ or 2009$).ed. (3,555,234)
  20. 18 and 19 (356)
  21. (adalimumab or humira or D2E7 or (D2 adj E7)).ti,ab,rn. (1161)
  22. 11 and 14 and 21 (143)
  23. 20 or 22 (399)

MEDLINE In-Process & Other Non-Indexed Citations: OvidSP

The MEDLINE In-Process & Other Non-Indexed Citations search, database dated 8 June 2009, was carried out on 9 June 2009 and identified five records.

The strategy sess the Cochrane Highly Sensitive Search Strategy for identifying randomised trials in MEDLINE, sensitivity-maximising version (lines 1–11).

  1. randomized controlled trial.pt. (387)
  2. controlled clinical trial.pt. (40)
  3. randomized.ab. (7406)
  4. placebo.ab. (3160)
  5. drug therapy.fs. (20)
  6. randomly.ab. (8231)
  7. trial.ab. (7527)
  8. groups.ab. (42,954)
  9. or/1-8 (56,348)
  10. (animals not (humans and animals)).sh. (8)
  11. 9 not 10 (56,346)
  12. Arthritis, Psoriatic/ (1)
  13. (psoria$adj2 (arthrit$or arthropath$)).ti,ab. (125)
  14. 12 or 13 (125)
  15. (etanercept or enbrel).ti,ab,rn. (164)
  16. (infliximab or remicade).ti,ab,rn. (287)
  17. (adalimumab or humira or D2E7 or (D2 adj E7)).ti,ab,rn. (110)
  18. or/15-17 (438)
  19. 11 and 14 and 18 (5)

EMBASE: OvidSP

The EMBASE search covered the date range 1980–2009 week 23 for adalimumab and 1 January 2004 to week 23 2009, using the search field ‘em: Entry Week’, for etanercept and infliximab. The search was carried out on 9 June 2009 and identified 369 records.

The strategy uses the Hedges Team best-sensitivity strategy for detecting clinically sound treatment studies in EMBASE (lines 17–20).203

Note: A pragmatic approach was taken to reduce the number of irrelevant records retrieved and to negate the over indexing of records in EMBASE; EMTREE drug terms were focused in this strategy.

  1. Psoriatic Arthritis/ (4225)
  2. (psoria$adj2 (arthrit$or arthropath$)).ti,ab. (3339)
  3. 1 or 2 (5024)
  4. *Etanercept/ (1973)
  5. (etanercept or enbrel).ti,ab. (2192)
  6. *Infliximab/ (3482)
  7. (infliximab or remicade).ti,ab. (3991)
  8. or/4-7 (6134)
  9. (2004$or 2005$or 2006$or 2007$or 2008$or 2009$).em. (3,193,493)
  10. 8 and 9 (4694)
  11. *Adalimumab/ (881)
  12. (adalimumab or humira or D2E7 or (D2 adj E7)).ti,ab. (958)
  13. 11 or 12 (1236)
  14. 3 and 10 (500)
  15. 3 and 13 (219)
  16. 14 or 15 (561)
  17. random$.tw. (399,406)
  18. clinical trial$.mp. (608,378)
  19. exp Health Care Quality/ (802,714)
  20. or/17-19 (1,446,048)
  21. 16 and 20 (369)

CENTRAL: The Cochrane Library

Issue 2, 2009, of The Cochrane Library was searched to identify trials on CENTRAL. The etanercept and infliximab search covered the date range 2004–2009. The search for adalimumab had no date limits. The search was carried out on 9 June 2009 and identified 37 records.

#1.

MeSH descriptor Arthritis, Psoriatic, this term only (99)

#2.

(psoria* NEAR/2 arthrit*) in Clinical Trials (132)

#3.

(psoria* NEAR/2 arthropath*) in Clinical Trials (6)

#4.

(#1 OR #2 OR #3) (199)

#5.

(etanercept or enbrel):ti,ab,kw, from 2004 to 2009 in Clinical Trials (184)

#6.

(infliximab or remicade):ti,ab,kw, from 2004 to 2009 in Clinical Trials (224)

#7.

(adalimumab or humira or D2E7 or (D2 adj E7)):ti,ab,kw in Clinical Trials (91)

#8.

(#5 OR #6 OR #7) (579)

#9.

(#4 AND #8) (37)

SCI: ISI Web of Knowledge

The SCI search covered the date range 1990–2009 for adalimumab and 2004–9 for etanercept and infliximab. The search was carried out on 9 June 2009 and identified 302 records.

The strategy uses the terms used in the 2006 HTA report73 to identify RCTs in the SCI (lines #1–7).

# 13.

302 #10 or #12

Databases=SCI-EXPANDED Timespan=All Years

# 12.

108 #7 and #8 and #11

Databases=SCI-EXPANDED Timespan=All Years

# 11.

1,676 TS=(adalimumab or humira or D2E7 or “D2 E7”)

Databases=SCI-EXPANDED Timespan=All Years

# 10.

275 #7 and #8 and #9

Databases=SCI-EXPANDED Timespan=2004–2009

# 9.

9,327 TS=(etanercept or enbrel or infliximab or remicade)

Databases=SCI-EXPANDED Timespan=All Years

# 8.

4,706 TS=((psoria* same arthrit*) or (psoria* same arthropath*))

Databases=SCI-EXPANDED Timespan=All Years

# 7.

>100,000 #5 not #6

Databases=SCI-EXPANDED Timespan= All Years

# 6.

>100,000 TS=(animal or animals or dog or dogs or hamster* or mice or mouse or rat or rats or bovine or sheep or guinea*)

Databases=SCI-EXPANDED Timespan=All Years

# 5.

>100,000 #1 or #2 or #3 or #4

Databases=SCI-EXPANDED Timespan=All Years

# 4.

>100,000 TS=(placebo* or random* or control* or prospectiv* or volunteer*)

Databases=SCI-EXPANDED Timespan=All Years

# 3.

>100,000 TS=(clinic* same trial*)

Databases=SCI-EXPANDED Timespan=All Years

# 2.

>100,000 TS=((singl* or doubl* or trebl* or tripl*) SAME (blind* or mask*))

Databases=SCI-EXPANDED Timespan=All Years

# 1.

>100,000 TS=((study or studies) SAME design*)

Databases=SCI-EXPANDED Timespan=All Years

CPCI-S: ISI Web of Knowledge

The CPCI-S search covered the date range 1990–2009 for adalimumab and 2004–9 for etanercept and infliximab. The search was carried out on 9 June 2009 and identified 37 records.

The strategy uses the terms used in the 2006 HTA report73 to identify RCTs in the CPCI-S (previously ISI Science and Technology Proceedings) (lines #1–7).

# 13.

37 #10 or #12

Databases=CPCI-S Timespan=1990–2009

# 12.

12 #7 and #8 and #11

Databases=CPCI-S Timespan=1990–2009

# 11.

635 TS=(adalimumab or humira or D2E7 or “D2 E7”)

Databases=CPCI-S Timespan=1990–2009

# 10.

29 #7 and #8 and #9

Databases=CPCI-S Timespan=2004–2009

# 9.

2,588 TS=(etanercept or enbrel or infliximab or remicade)

Databases=CPCI-S Timespan=1990–2009

# 8.

797 TS=((psoria* same arthrit*) or (psoria* same arthropath*))

Databases=CPCI-S Timespan=1990–2009

# 7.

>100,000 #5 not #6

Databases=CPCI-S Timespan=1990–2009

# 6.

>100,000 TS=(animal or animals or dog or dogs or hamster* or mice or mouse

or rat or rats or bovine or sheep or guinea*)

Databases=CPCI-S Timespan=1990–2009

# 5.

>100,000 #1 or #2 or #3 or #4

Databases=CPCI-S Timespan=1990–2009

# 4.

>100,000 TS=(placebo* or random* or control* or prospectiv* or volunteer*)

Databases=CPCI-S Timespan=1990–2009

# 3.

22,210 TS=(clinic* same trial*)

Databases=CPCI-S Timespan=1990–2009

# 2.

15,096 TS=((singl* or doubl* or trebl* or tripl*) SAME (blind* or mask*))

Databases=CPCI-S Timespan=1990–2009

# 1.

>100,000 TS=((study or studies) SAME design*)

Databases=CPCI-S Timespan=1990–2009

ClinicalTrials.gov

The ClinicalTrials.gov registry was searched for ongoing trials information. The search was carried out on 9 June 2009 and identified 27 studies.

Basic Search: ((psoriatic arthritis OR psoriatic arthropathy) AND (etanercept OR enbrel OR infliximab OR remicade OR adalimumab or humira or D2E7 or ‘D2 E7’))

mRCT

The mRCT was searched for ongoing trials information. The search was carried out on 10 June 2009 and identified 41 studies.

SEARCH FOR [all registers]: ((“psoriatic arthritis” OR “psoriatic arthropathy”) AND (etanercept OR enbrel OR infliximab OR remicade OR adalimumab or humira or D2E7 or “D2 E7”))

Cost-effectiveness search

MEDLINE: OvidSP

The MEDLINE search covered the date range 1950 to week 1 June 2009 for adalimumab and 1 April 2004 to week 1 June 2009, using the search field ‘ed: Entry Date’, for etanercept and infliximab. The search was carried out on 11 June 2009 and identified 24 records.

The strategy uses the CRD NHS EED strategy for identifying economic evaluations in MEDLINE (lines 13–39).204

  1. Arthritis, Psoriatic/ (2225)
  2. (psoria$adj2 (arthrit$or arthropath$)).ti,ab. (3601)
  3. 1 or 2 (4143)
  4. (etanercept or enbrel).ti,ab,rn. (2086)
  5. (infliximab or remicade).ti,ab,rn. (4731)
  6. 4 or 5 (5906)
  7. 3 and 6 (488)
  8. (200404$or 200405$or 200406$or 200407$or 200408$or 200409$ or 200410$or 200411$or 200412$or 2005$or 2006$or 2007$ or 2008$or 2009$).ed. (3,568,700)
  9. 7 and 8 (387)
  10. (adalimumab or humira or D2E7 or (D2 adj E7)).ti,ab,rn. (1164)
  11. 3 and 10 (152)
  12. 9 or 11 (432)
  13. economics/ (25,433)
  14. exp “Costs and Cost Analysis”/ (143,147)
  15. VALUE OF LIFE/ (5039)
  16. economics, dental/ (1776)
  17. exp economics, hospital/ (15,981)
  18. economics, medical/ (7044)
  19. economics, nursing/ (3784)
  20. economics, pharmaceutical/ (2048)
  21. (econom$or cost or costs or costly or costing or price or prices or pricing or pharmacoeconom$).ti,ab. (300,152)
  22. (expenditure$not energy).ti,ab. (12,542)
  23. (value adj1 money).ti,ab. (12)
  24. budget$.ti,ab. (12,911)
  25. or/13-24 (407,009)
  26. ((energy or oxygen) adj cost).ti,ab. (2082)
  27. (metabolic adj cost).ti,ab. (512)
  28. ((energy or oxygen) adj expenditure).ti,ab. (11,540)
  29. or/26-28 (13,584)
  30. 25 not 29 (403,828)
  31. letter.pt. (654,164)
  32. editorial.pt. (239,274)
  33. historical article.pt. (272,822)
  34. or/31-33 (1,155,003)
  35. 30 not 34 (381,317)
  36. Animals/ (4,399,394)
  37. Humans/ (10,777,302)
  38. 36 not (36 and 37) (3,292,558)
  39. 35 not 38 (361,076)
  40. 12 and 39 (24)

MEDLINE In-Process & Other Non-Indexed Citations: OvidSP

The MEDLINE In-Process & Other Non-Indexed Citations search, database dated 11 June 2009, was carried out on 12 June 2009 and identified one record.

The strategy uses the CRD NHS EED strategy for identifying economic evaluations in MEDLINE (lines 9–35).

  1. Arthritis, Psoriatic/ (1)
  2. (psoria$adj2 (arthrit$or arthropath$)).ti,ab. (130)
  3. 1 or 2 (130)
  4. (etanercept or enbrel).ti,ab,rn. (174)
  5. (infliximab or remicade).ti,ab,rn. (298)
  6. (adalimumab or humira or D2E7 or (D2 adj E7)).ti,ab,rn. (113)
  7. or/4-6 (457)
  8. 3 and 7 (21)
  9. economics/ (1)
  10. exp “Costs and Cost Analysis”/ (7)
  11. VALUE OF LIFE/ (0)
  12. economics, dental/ (0)
  13. exp economics, hospital/ (11)
  14. economics, medical/ (0)
  15. economics, nursing/ (0)
  16. economics, pharmaceutical/ (0)
  17. (econom$or cost or costs or costly or costing or price or prices or pricing or pharmacoeconom$).ti,ab. (15,266)
  18. (expenditure$not energy).ti,ab. (422)
  19. (value adj1 money).ti,ab. (2)
  20. budget$.ti,ab. (620)
  21. or/9-20 (15,898)
  22. ((energy or oxygen) adj cost).ti,ab. (103)
  23. (metabolic adj cost).ti,ab. (14)
  24. ((energy or oxygen) adj expenditure).ti,ab. (435)
  25. or/22-24 (536)
  26. 21 not 25 (15,762)
  27. letter.pt. (14,507)
  28. editorial.pt. (8936)
  29. historical article.pt. (2)
  30. or/27-29 (23,445)
  31. 26 not 30 (15,515)
  32. Animals/ (12)
  33. Humans/ (105)
  34. 32 not (32 and 33) (8)
  35. 31 not 34 (15,515)
  36. 8 and 35 (1)

EMBASE: OvidSP

The EMBASE search covered the date range 1980–2009 week 23 for adalimumab and 1 January 2004–9 week 23, using the search field “em: Entry Week”, for etanercept and infliximab. The search was carried out on 12 June 2009 and identified 80 records.

The strategy uses the CRD NHS EED strategy for identifying economic evaluations in EMBASE (lines 17–43).

Note: A pragmatic approach was taken to reduce the number of irrelevant records retrieved and to negate the over indexing of records in EMBASE; EMTREE drug terms were focused in this strategy.

  1. Psoriatic Arthritis/ (4225)
  2. (psoria$adj2 (arthrit$or arthropath$)).ti,ab. (3339)
  3. 1 or 2 (5024)
  4. *Etanercept/ (1973)
  5. (etanercept or enbrel).ti,ab. (2192)
  6. *Infliximab/ (3482)
  7. (infliximab or remicade).ti,ab. (3991)
  8. or/4-7 (6134)
  9. (2004$or 2005$or 2006$or 2007$or 2008$or 2009$).em. (3,193,493)
  10. 8 and 9 (4694)
  11. *Adalimumab/ (881)
  12. (adalimumab or humira or D2E7 or (D2 adj E7)).ti,ab. (958)
  13. 11 or 12 (1236)
  14. 3 and 10 (500)
  15. 3 and 13 (219)
  16. 14 or 15 (561)
  17. Health Economics/ (10,611)
  18. exp Economic Evaluation/ (104,472)
  19. exp “Health Care Cost”/ (107,017)
  20. exp PHARMACOECONOMICS/ (56,975)
  21. (econom$or cost or costs or costly or costing or price or prices or pricing or pharmacoeconomic$).tw. (234,263)
  22. (expenditure$not energy).ti,ab. (9859)
  23. (value adj2 money).ti,ab. (462)
  24. budget$.ti,ab. (8863)
  25. or/17-24 (347,643)
  26. (metabolic adj cost).ti,ab. (388)
  27. ((energy or oxygen) adj cost).ti,ab. (1707)
  28. ((energy or oxygen) adj expenditure).ti,ab. (10,088)
  29. or/26-28 (11,689)
  30. 25 not 29 (345,077)
  31. (letter or note or editorial).pt. (925,192)
  32. 30 not 31 (298,277)
  33. exp Animal/ (18,276)
  34. exp Animal Experiment/ (1,298,147)
  35. Nonhuman/ (3,232,877)
  36. (rat or rats or mouse or mice or hamster or hamsters or animal or animals or dog or dogs or cat or cats or bovine or sheep).ti,ab. (1,737,766)
  37. or/33-36 (3,643,672)
  38. exp human/ (6,568,828)
  39. exp Human Experiment/ (257,542)
  40. 38 or 39 (6,569,696)
  41. 37 not (37 and 40) (2,983,952)
  42. 32 not 41 (274,297)
  43. 16 and 42 (80)

CENTRAL: The Cochrane Library

A search of CENTRAL was not repeated for cost-effectiveness evidence. The search carried out on 9 June 2009 (shown in Cinical effectiveness: search for RCTs) was not limited by study design and would also have identified economic evaluations.

SCI: ISI Web of Knowledge

The SCI search covered the date range 1900–2009 for adalimumab and 2004–9 for etanercept and infliximab. The search was carried out on 12 June 2009 and identified 31 records.

The strategy uses the terms used in the 2006 HTA report73 to identify economic evaluations in the SCI (lines #7–10).

# 10.

31 #8 not #9

Databases=SCI-EXPANDED Timespan=1900–2009

# 9.

>100,000 TS=(animal or animals or dog or dogs or hamster* or mice or mouse or rat or rats or bovine or sheep or guinea*)

Databases=SCI-EXPANDED Timespan=1900–2009

# 8.

33 #6 and #7

Databases=SCI-EXPANDED Timespan=1900–2009

# 7.

>100,000 TS=(econom* or cost or costs or costly or costing or price or prices or pricing or pharmacoeconom* or budget*)

Databases=SCI-EXPANDED Timespan=1900–2009

# 6.

666 #3 or #5

Databases=SCI-EXPANDED Timespan=1900–2009

# 5.

211 #1 and #4

Databases=SCI-EXPANDED Timespan=1900–2009

# 4.

1,699 TS=(adalimumab or humira or D2E7 or “D2 E7”)

Databases=SCI-EXPANDED Timespan=1900–2009

# 3.

570 #1 and #2

Databases=SCI-EXPANDED Timespan=1900–2009

# 2.

7,383 TS=(etanercept or enbrel or infliximab or remicade)

Databases=SCI-EXPANDED Timespan=2004–2009

# 1.

4,736 TS=((psoria* same arthrit*) or (psoria* same arthropath*))

Databases=SCI-EXPANDED Timespan=1900–2009

CPCI-S: ISI Web of Knowledge

The CPCI-S search covered the date range 1990–2009 for adalimumab and 2004–9 for etanercept and infliximab. The search was carried out on 12 June 2009 and identified three records.

The strategy uses the terms used in the 2006 HTA report to identify economic evaluations in the CPCI-S (previously ISI Science and Technology Proceedings) (lines #7–10).

# 10.

3 #8 not #9

Databases=CPCI-S Timespan=1990–2009

# 9.

>100,000 TS=(animal or animals or dog or dogs or hamster* or mice or mouse or rat or rats or bovine or sheep or guinea*)

Databases=CPCI-S Timespan=1990–2009

# 8.

3 #6 and #7

Databases=CPCI-S Timespan=1990–2009

# 7.

>100,000 TS=(econom* or cost or costs or costly or costing or price or prices or pricing or pharmacoeconom* or budget*)

Databases=CPCI-S Timespan=1990–2009

# 6.

196 #3 or #5

Databases=CPCI-S Timespan=1990–2009

# 5.

62 #1 and #4

Databases=CPCI-S Timespan=1990–2009

# 4.

651 TS=(adalimumab or humira or D2E7 or “D2 E7”)

Databases=CPCI-S Timespan=1990–2009

# 3.

140 #1 and #2

Databases=CPCI-S Timespan=1990–2009

# 2.

2,192 TS=(etanercept or enbrel or infliximab or remicade)

Databases=CPCI-S Timespan=2004–2009

# 1.

814 TS=((psoria* same arthrit*) or (psoria* same arthropath*))

Databases=CPCI-S Timespan=1990–2009

NHS EED

The NHS EED was searched for economic evaluations. As no records were identified in the 2006 HTA review, no date limits were set. The search was carried out on 12 June 2009 and identified seven records.

Note: The strategy was run across the entire CRD databases and the final results shown here, 20 records, relate to the total number of records found.

  1. # 1 MeSH Arthritis, Psoriatic (22)
  2. # 2 (psoria* NEAR arthrit*) (43)
  3. # 3 (psoria* NEAR arthropath*) (1)
  4. # 4 #1 or #2 or #3 (44)
  5. # 5 etanercept OR enbrel OR infliximab OR remicade (165)
  6. # 6 adalimumab OR humira OR D2E7 OR “D2 AND E7” (48)
  7. # 7 #5 or #6 (182)
  8. # 8 #4 and #7 (20)

HEED

The HEED was searched for economic evaluations. As no records were identified in the 2006 HTA review, no date limits were set. The search was carried out on 12 June 2009 and identified eight records.

Compound Search

All Data: ((psoria* AND arthrit*) OR (psoria* AND arthropath*))

AND

All Data: etanercept OR enbrel OR infliximab OR remicade OR adalimumab OR humira OR D2E7 OR ‘D2 E7’

EconLit: OvidSP

The American Economic Association's electronic bibliography, EconLit, database was searched for economic evaluations. The search carried out on 12 June 2009, covering the date range 1969–May 2009, identified no records.

  1. (psoria$adj2 (arthrit$or arthropath$)).ti,ab. (0)
  2. (etanercept or enbrel or infliximab or remicade or adalimumab or humira or D2E7 or “D2 E7”).ti,ab. (3)
  3. #1 and #2 (0)

Additional searches

Side-effects/adverse effects search

The following resources were searched for information on side-effects:

Additional information on side-effects was gathered by supplementary searches. The following searches were designed to capture the major side-effects that had been identified as arising from the use of etanercept, infliximab or adalimumab: urinary tract infections, lower respiratory tract infections, skin infections, bone infections, joint infections, malignancy, and the reactivation of latent TB.

A pragmatic approach to searching was adopted for the supplementary side-effects search. This can be seen in the reliance of indexed terms to search for the side-effects and the use of subheadings linked to specific side-effects, such as the MeSH subheading ‘Chemically Induced’ and the EMTREE subheading ‘Side Effect’. This search approach enhances the precision of a search but has an unknown effect on its sensitivity.

MEDLINE: OvidSP

The MEDLINE search covered the date range 1950 to week 1 June 2009. The search was carried out on 16 June 2009 and identified 60 records.

  1. (etanercept or enbrel).ti,ab. (2086)
  2. (infliximab or remicade).ti,ab. (3743)
  3. (adalimumab or humira or D2E7 or (D2 adj E7)).ti,ab. (878)
  4. or/1-3 (5297)
  5. Safety/ (26,929)
  6. (safe or safety).ti,ab. (271,847)
  7. (side effect or side effects).ti,ab. (130,142)
  8. treatment emergent.ti,ab. (867)
  9. undesirable effect$.ti,ab. (1448)
  10. tolerability.ti,ab. (19,551)
  11. Drug Toxicity/ (2820)
  12. toxicity.ti,ab. (173,622)
  13. Adverse Drug Reaction Reporting Systems/ (3900)
  14. adrs.ti,ab. (975)
  15. (adverse adj3 (effect or effects or reaction or reactions or event or events or outcome or outcomes)).ti,ab. (147,732)
  16. (undesir$adj2 (effect or effects or reaction or reactions or event or events or outcome or outcomes)).ti,ab. (4632)
  17. Drug Hypersensitivity/ (17,725)
  18. (hypersensit$or hyper sensit$).ti,ab. (45,094)
  19. harm$.ti,ab. (54,739)
  20. or/5-19 (750,762)
  21. 4 and 20 (1654)
  22. exp Infection/ci [Chemically Induced] (2859)
  23. exp Urinary Tract Infections/ci [Chemically Induced] (61)
  24. exp Respiratory Tract Infections/ci [Chemically Induced] (3678)
  25. exp Skin Diseases, Infectious/ci [Chemically Induced] (451)
  26. exp Bone Diseases, Infectious/ (27,676)
  27. exp Arthritis, Infectious/ci [Chemically Induced] (55)
  28. exp Neoplasms/ci [Chemically Induced] (50,219)
  29. exp Tuberculosis/ci [Chemically Induced] (315)
  30. or/22-29 (84,100)
  31. 21 and 30 (60)
  32. (animals not (humans and animals)).sh. (3,292,558)
  33. 31 not 32 (60)

EMBASE: OvidSP

The EMBASE search covered the date range 1980–2009 week 24. The search was carried out on 17 June 2009 and identified 648 records.

Note: A pragmatic approach was taken to reduce the number of irrelevant records retrieved and to negate the over indexing of records in EMBASE; EMTREE drug terms were focused in this strategy.

  1. (etanercept or enbrel).ti,ab. (2202)
  2. (infliximab or remicade).ti,ab. (3999)
  3. (adalimumab or humira or D2E7 or (D2 adj E7)).ti,ab. (960)
  4. or/1-3 (5648)
  5. *Etanercept/ (1979)
  6. *Infliximab/ (3486)
  7. *Adalimumab/ (882)
  8. or/5-7 (5086)
  9. 4 or 8 (6595)
  10. (safe or safety).ti,ab. (246,785)
  11. side effect$.ti,ab. (123,415)
  12. treatment emergent.ti,ab. (963)
  13. undesirable effect$.ti,ab. (1421)
  14. tolerability.ti,ab. (22,410)
  15. toxicity.ti,ab. (164,169)
  16. adrs.ti,ab. (1214)
  17. (adverse adj3 (effect or effects or reaction or reactions or event or events or outcome or outcomes)).ti,ab. (144,000)
  18. Safety/or Drug Safety/ (183,510)
  19. Side Effect/ (94,185)
  20. Adverse Drug Reaction/ (95,592)
  21. Drug Tolerability/ (54,359)
  22. Toxicity/or Drug Toxicity/ (47,998)
  23. Drug Surveillance Program/ (7235)
  24. Adverse Outcome/ (1414)
  25. hypersensit$.ti,ab. (35,011)
  26. harm$.ti,ab. (46,014)
  27. Drug Hypersensitivity/ (25,074)
  28. or/10-27 (892,235)
  29. 9 and 28 (2822)
  30. *Etanercept/ae, to [Adverse Drug Reaction, Drug Toxicity] (917)
  31. *Infliximab/ae, to [Adverse Drug Reaction, Drug Toxicity] (1636)
  32. *Adalimumab/ae, to [Adverse Drug Reaction, Drug Toxicity] (442)
  33. or/30-32 (2470)
  34. 29 or 33 (3651)
  35. Urinary Tract Infection/si [Side Effect] (2059)
  36. Lower Respiratory Tract Infection/si [Side Effect] (144)
  37. Skin Infection/si [Side Effect] (488)
  38. Bone Infection/si [Side Effect] (26)
  39. Infectious Arthritis/si [Side Effect] (55)
  40. Neoplasm/si [Side Effect] (452)
  41. Tuberculosis/si [Side Effect] (1297)
  42. or/35-41 (4150)
  43. 34 and 42 (648)
© 2011, Crown Copyright.

Included under terms of UK Non-commercial Government License.

Bookshelf ID: NBK109479

Views

Other titles in this collection

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...